INS and Hypoglycemia: Although the amount of reabsorbed glucose increases up to two- to three-fold during hyperglycemia, this novel SGLT2 inhibitor can significantly reduce HbA1c, fasting blood glucose levels, body weight, and total daily insulin dosing without increasing the risk of hypoglycemia; it may also confer renal protection by minimizing the glomerular hyperfiltration that arises in diabetes [11–13].